224 related articles for article (PubMed ID: 25593113)
21. Quantitative Assessment of Early [
Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R
J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366
[TBL] [Abstract][Full Text] [Related]
22. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry.
Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hanna L; Stine SH; Coleman RE
Cancer; 2009 Jan; 115(2):410-8. PubMed ID: 19016303
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of extraskeletal computed tomography findings on 18F-NaF PET/CT performed for osseous metastatic disease evaluation.
Guo HH; Moradi F; Iagaru A
Nucl Med Commun; 2016 Sep; 37(9):975-82. PubMed ID: 27111100
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer.
De Giorgi U; Mego M; Rohren EM; Liu P; Handy BC; Reuben JM; Macapinlac HA; Hortobagyi GN; Cristofanilli M; Ueno NT
J Nucl Med; 2010 Aug; 51(8):1213-8. PubMed ID: 20660382
[TBL] [Abstract][Full Text] [Related]
25. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Liu D; Shields AF; Gareen IF; Hanna L; Stine SH; Coleman RE
J Clin Oncol; 2008 May; 26(13):2155-61. PubMed ID: 18362365
[TBL] [Abstract][Full Text] [Related]
26. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
[TBL] [Abstract][Full Text] [Related]
27. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.
Hetzel M; Arslandemir C; König HH; Buck AK; Nüssle K; Glatting G; Gabelmann A; Hetzel J; Hombach V; Schirrmeister H
J Bone Miner Res; 2003 Dec; 18(12):2206-14. PubMed ID: 14672356
[TBL] [Abstract][Full Text] [Related]
28. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
29. Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases.
Simoncic U; Perlman S; Liu G; Staab MJ; Straus JE; Jeraj R
Clin Genitourin Cancer; 2015 Feb; 13(1):e7-e17. PubMed ID: 25128349
[TBL] [Abstract][Full Text] [Related]
30. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
[TBL] [Abstract][Full Text] [Related]
31. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial.
Iagaru A; Mittra E; Mosci C; Dick DW; Sathekge M; Prakash V; Iyer V; Lapa P; Isidoro J; de Lima JM; Gambhir SS
J Nucl Med; 2013 Feb; 54(2):176-83. PubMed ID: 23243299
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.
Schirrmeister H; Guhlmann A; Elsner K; Kotzerke J; Glatting G; Rentschler M; Neumaier B; Träger H; Nüssle K; Reske SN
J Nucl Med; 1999 Oct; 40(10):1623-9. PubMed ID: 10520701
[TBL] [Abstract][Full Text] [Related]
33. No Added Value of
Zacho HD; Jochumsen MR; Langkilde NC; Mortensen JC; Haarmark C; Hendel HW; Jensen JB; Petersen LJ
J Nucl Med; 2019 Dec; 60(12):1713-1716. PubMed ID: 31147402
[TBL] [Abstract][Full Text] [Related]
34. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
Subramaniam RM; Shields AF; Sachedina A; Hanna L; Duan F; Siegel BA; Hillner BE
Oncologist; 2016 Sep; 21(9):1079-84. PubMed ID: 27401896
[TBL] [Abstract][Full Text] [Related]
35. Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice.
Bastawrous S; Bhargava P; Behnia F; Djang DS; Haseley DR
Radiographics; 2014; 34(5):1295-316. PubMed ID: 25208282
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.
Yen RF; Chen CY; Cheng MF; Wu YW; Shiau YC; Wu K; Hong RL; Yu CJ; Wang KL; Yang RS
Nucl Med Commun; 2010 Jul; 31(7):637-45. PubMed ID: 20389259
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of bone-seeking novel radiotracer
Passah A; Tripathi M; Ballal S; Yadav MP; Kumar R; Roesch F; Meckel M; Sarathi Chakraborty P; Bal C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):41-49. PubMed ID: 27455986
[TBL] [Abstract][Full Text] [Related]
38. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
40. Use of
Mogensen AW; Petersen LJ; Torp-Pedersen C; Nørgaard M; Pank MT; Zacho HD
BMJ Open; 2022 Jun; 12(6):e058898. PubMed ID: 35705343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
